Feature | VIVA | November 14, 2019

VIVA 2019 Late-breaking Clinical Trials

The latest clinical data in vascular medicine and peripheral vascular interventions

Viva conference late breaking clinical trials, #VIVA19 #VIVA #VIVA2019

November 14, 2019 — The results of the 21 late-breaking clinical trials presented for the first time at Vascular Interventional Advances (VIVA) 2019 conference. These results were presented in four different sessions on Nov. 5-6, 2019, in VIVA's Global Theater. VIVA highlights the latest science in vascular and peripheral vascular interventions.
 

Tuesday Late-breakers, November 5:

   • No Increased Mortality for the Zilver PTX Drug-Eluting Stent Compared to Uncoated Devices, presented by Michael Dake, M.D.

   • A Novel Sustained Sirolimus Release Eluting Balloon: 2-Year Data From the SELUTION SFA Trial, presented by Thomas Zeller, M.D., Ph.D.

   • RANGER II SFA: Randomized Trial of RANGER DCB vs. PTA in the SFA, presented by Ravish Sachar, M.D.

   • 4-Year Outcomes From the IN.PACT Global Study, presented by Thomas Zeller, M.D., Ph.D.

   • DCB vs POBA After B-laser Atherectomy Shows No Difference, presented by John Rundback, M.D.

   • Two-Year Outcomes From the IMPERIAL Randomized Trial of Eluvia and Zilver PTX, presented by Osamu Iida, M.D.

 

   • Full Cohort 24-Month Safety and Efficacy Results of the VMI-CFA Common Femoral Stenting Trial, presented by Koen Deloose, M.D.

   • Nexus Aortic Arch Branch Stent-Graft System – Mid-Term Results, presented by Mario Lachat, M.D.

   • Revolution Rotational Atherectomy System IDE Experience, presented by Jeffrey Carr, M.D.

   • 1-year Results From the MIMICS-3D Registry: Investigating the BioMimics 3D Stent, presented by Michael Lichtenberg, M.D.

   • Treatment of BTK Disease With a Novel Device: Update on the DEEPER OUS Trial, presented by Thomas Zeller, M.D., Ph.D.

 

Wednesday Late-breakers, November 6:

   • 6-Months Results of TOBA II BTK, presented by George Adams, M.D.

   • 5-Year ABSORB BTK Trial Results, presented by Ramon Varcoe, MBBS, MS, Ph.D.

   • Results of the PROMISE I Trial Using the LimbFlow Bypass System in Limb-threatening Ischemia, presented by Daniel Clair, M.D.

   • Initial 12-Month Outcomes From the TANGO Trial (Adventitial Temsirolimus in BTK Lesions), presented by Ehrin Armstrong, M.D.

   • The Ulysse Registry Shows Benefit of Ultrasoundplasty in Below-the-knee Interventions, presented by Costantino Del Giudice, M.D., Ph.D.

    
   • IN.PACT AV Access 6-month Lesion Outcomes, presented by Robert Lookstein, M.D., MHCDL

   • Lateral Subdermic Plexus Insufficiency: A Paradigm Shift With Restless Leg Syndrome, presented by Swar Shah, M.D.

   • Early Outcomes From the ClotTriever (CLOUT) Registry in DVT, presented by David Dexter, M.D.

   • Indigo Aspiration System for Acute Pulmonary Embolism, presented by Akhilesh Sista, M.D.

   • 1-Year Results of the DISAPEAR Registry, presented by Steven Kum, M.D.

 

 
Related Late-breaking Cardiovascular Trials:

ACC 2019 Late-breaking Presentations

Late-breaking Interventional Cardiology Presentations at SCAI 2019

American Heart Association 2018 Late-breaking Trials

TCT 2019 Late-breaking Presentations

American Heart Association 2019 Late-breaking Trials

Related Content

A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th